A detailed history of Geode Capital Management, LLC transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 208,748 shares of AADI stock, worth $597,019. This represents 0.0% of its overall portfolio holdings.

Number of Shares
208,748
Previous 206,443 1.12%
Holding current value
$597,019
Previous $301,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.32 - $2.06 $3,042 - $4,748
2,305 Added 1.12%
208,748 $430,000
Q2 2024

Aug 09, 2024

SELL
$1.46 - $2.31 $281,470 - $445,340
-192,788 Reduced 48.29%
206,443 $301,000
Q1 2024

May 13, 2024

BUY
$1.59 - $2.44 $5,364 - $8,232
3,374 Added 0.85%
399,231 $934,000
Q4 2023

Feb 13, 2024

BUY
$1.97 - $5.41 $57,285 - $157,317
29,079 Added 7.93%
395,857 $799,000
Q3 2023

Nov 13, 2023

BUY
$4.84 - $7.13 $165,842 - $244,309
34,265 Added 10.3%
366,778 $1.78 Million
Q2 2023

Aug 11, 2023

BUY
$6.84 - $8.56 $415,967 - $520,567
60,814 Added 22.38%
332,513 $2.27 Million
Q1 2023

May 15, 2023

BUY
$6.85 - $13.0 $72,699 - $137,969
10,613 Added 4.06%
271,699 $1.97 Million
Q4 2022

Feb 13, 2023

BUY
$11.99 - $14.5 $56,125 - $67,874
4,681 Added 1.83%
261,086 $3.35 Million
Q3 2022

Nov 14, 2022

SELL
$12.03 - $14.22 $665,403 - $786,536
-55,312 Reduced 17.74%
256,405 $3.62 Million
Q2 2022

Aug 12, 2022

BUY
$11.57 - $17.92 $1.33 Million - $2.05 Million
114,533 Added 58.08%
311,717 $3.84 Million
Q1 2022

May 13, 2022

BUY
$16.65 - $24.97 $1,848 - $2,771
111 Added 0.06%
197,184 $3.35 Million
Q4 2021

Feb 11, 2022

BUY
$19.32 - $29.02 $3.26 Million - $4.9 Million
168,970 Added 601.25%
197,073 $4.76 Million
Q3 2021

Nov 12, 2021

BUY
$25.52 - $41.85 $717,188 - $1.18 Million
28,103 New
28,103 $825,000

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $60.1M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.